Medivir: Nomination Committee Proposes New Board of Directors Ahead of 2013
STOCKHOLM -- March 21, 2013
Medivir AB (STO:MVIR-B) today published the proposal for the new Board of
Directors submitted by the Nomination Committee ahead of the 2013 Annual
The 2012-2013 Nomination Committee comprises representatives of the three
largest shareholders at the end of Q3 2012 who accepted the invitation to
become members of the Nomination Committee, and the Chairman of the Board. The
composition of the 2012-2013 Nomination Committee was as follows:
Anders Algotson, Chairman of the Nomination Committee, representing AFA
Försäkring Annelie Enquist, representing Skandia Fonder Göran Pettersson,
Chairman of the Board of Medivir AB Bo Öberg, representing the class A
The Nomination Committee now proposes, ahead of the 2013 Annual General
Meeting, that a new Board of Directors be appointed by means of the
re-election of the six existing Members of the Board, namely Björn C.
Andersson, Anna Malm Bernsten, Rolf A. Classon, Anders Hallberg, Ingemar
Kihlström, and Göran Pettersson, and the new election of two Members, namely
Birgitta Stymne Göransson and Bo Öberg. The Nomination Committee also proposes
the re-election of the Chairman of the Board, Göran Pettersson.
Birgitta Stymne Göransson, born 1957, is the CEO of Memira AB. Birgitta is a
graduate engineer who majored in biotechnology at the Royal Institute of
Technology in Stockholm and who also holds a Master of Business Administration
degree from Harvard Business School. Birgitta has many years’ experience of
senior executive positions in trade and industry and has worked in Sweden and
the rest of the Nordic region, and in the USA. She is currently a member of
the board of directors at Elekta AB, Rhenman & Partners Asset Management AB
and the Stockholm Chamber of Commerce.
Professor Bo Öberg, born 1939, is an adjunct professor in virology at
Karolinska Institutet and has 180 publications in virology and antiviral
research. Bo is a founder of Medivir and represents the class A shareholders.
He has been employed by Medivir since 1988 and has previously been a member of
Medivir’s board of directors during 1988 – 2009. Bo is currently a board
member at Beactica AB.
Medivir is an emerging research-based pharmaceutical company focused on
Medivir has world class expertise in polymerase and protease drug targets and
drug development which has resulted in a strong infectious disease R&D
portfolio. The Company’s key pipeline asset is simeprevir, a novel protease
inhibitor in late phase III clinical development for hepatitis C that is being
developed in collaboration with Janssen R&D Ireland.
Medivir has also a broad product portfolio with prescription pharmaceuticals
in the Nordics.
For more information about Medivir AB, please visit the Company’s website:
This information was brought to you by Cision http://news.cision.com
Rein Piir, EVP Corporate Affairs & IR
mobile: +46 708 537292
Press spacebar to pause and continue. Press esc to stop.